LTP001
This is an investigational medication being studied for the treatment of pulmonary arterial hypertension (PAH). It is being tested in both healthy volunteers and patients with PAH. The medication is being evaluated to understand how safe it is and how well it works when combined with standard treatments for PAH. This is a new drug that is still in the research phase, and its effects are being studied in people with moderate to severe PAH symptoms.

Standard-of-care medications
These are the currently approved and commonly used medications that patients with pulmonary arterial hypertension typically receive as part of their regular treatment. During the trial, patients will continue taking these established medications while also receiving either LTP001 or placebo.

Pulmonary Arterial Hypertension (PAH) – A rare condition that affects the blood vessels in the lungs, causing them to become narrowed and thickened. This narrowing makes it harder for blood to flow through the lungs, which increases blood pressure in the pulmonary arteries. The heart must work harder to pump blood through these narrowed arteries, leading to the enlargement and weakening of the right side of the heart over time. Symptoms typically develop gradually and may include shortness of breath during physical activity, fatigue, chest pain, and dizziness. The condition can affect people of all ages, though it’s more common in young adults and women.